E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
Phase 2
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01692197
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Three-Factor Eating Questionnaire in Measuring Eating Behavior in Adolescent and Young Adult Survivors of CNS Tumors
Completed
- Conditions
- Cancer Survivor
- Interventions
- Other: Nutritional AssessmentOther: Questionnaire Administration
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01682824
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Dexamethasone Dyspnea Study
Phase 2
Completed
- Conditions
- Advanced CancersHematologic DisorderSolid Tumors
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01670097
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Previously Treated Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AAdult Acute Promyelocytic Leukemia With PML-RARARecurrent Adult Acute Myeloid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01664897
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase 1
Completed
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: Anti-Thymocyte GlobulinBiological: Inotuzumab OzogamicinProcedure: Peripheral Blood Stem Cell TransplantationBiological: Rituximab
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01664910
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Technology and Navigation to Improve Survivorship Care
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Audio Recorded InterviewsBehavioral: Focus Group SessionBehavioral: QuestionnaireOther: Website Session
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT01663870
- Locations
- πΊπΈ
Lyndon B. Johnson Hospital, Houston, Texas, United States
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Phase 1
Completed
- Conditions
- LeukemiaAdvanced Cancers
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01653717
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01649622
A Social Media Approach to Improve Genetic Risk Communication Phase I
- Conditions
- Hereditary Diseases
- Interventions
- Behavioral: Audiotaped Focus GroupBehavioral: Demographic QuestionnaireBehavioral: Audiotaped InterviewBehavioral: WAMMI Inventory
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT01645904
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
Phase 2
Active, not recruiting
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT01644591
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States